Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDRH Discloses Guidance Priorities For Fiscal 2013

This article was originally published in The Gray Sheet

Executive Summary

The device center has posted its “A-list” and “B-list” of final and draft guidance documents it plans to release this fiscal year; the long-awaited regulatory framework for laboratory-developed tests didn’t make the lists.

You may also be interested in...



510(k) Program, Companion Dx Among Top FDA Guidance Priorities For FY 2014

CDRH says it plans to release the 510(k) program final guidance as well as the anticipated in vitro companion diagnostic final guidance next year. The device center has divided the 22 forthcoming guidance documents into an “A-list” and a “B-list,” based on its priorities and allocated resources.

FDA Charges Ahead With MDUFA III Implementation, Despite Budget Uncertainties

FDA has started carrying out its end of the medical device user fee agreement, with plans to issue several new guidance documents this fall, and the agency suggests that a short-term restriction on full user fee access should not inhibit its efforts.

Final FDA Bill: Device Provisions

Congress has settled on final language for the FDA Safety and Innovation Act. After Senate approval, the bill will go to the White House for President Obama’s signature.

Related Content

UsernamePublicRestriction

Register

MT031775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel